Citations 2
Low incidence of treatment-related myelodysplastic syndrome (tMDS) and acute myelogenous leukemia (tAML) in patients with non-Hodgkin's lymphoma (NHL) treated with ibritumomab tiuxetan
Emmanouilides, C., Czuczman, M. S., REVELL, S T, Wang, H. , Skikne, B. , Witzig, Thomas E. , Gordon, Leo I. , Foster, Paul , Molina, Aurelia Alañón
Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 6696-6696
Yttrium 90 ibritumomab tiuxetan is safe and effective in older patients with relapsed or refractory NHL
Schilder, Russell J., Emmanouilides, C., Vo, Katie D. , Darif, Mohamed, Witzig, Thomas E. , Flinn, Ian W. , Gordon, Leo I. , Molina, Aurelia Alañón
Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 6562-6562